Moderna News - July 31, 2026
🔴 Moderna is trading 4.6% down today after norovirus vaccine setback outweighs Q2 revenue beat
Moderna is trading 4.6% down now at $55.28 as investors focus on a Phase 3 norovirus vaccine setback that overshadowed a second-quarter revenue beat. • The...
🔴 Moderna is trading 4.5% down today after norovirus vaccine failure and Q2 earnings
Moderna is trading 4.5% down at $55.30 after the company reported Q2 2026 earnings and a clinical setback for its norovirus vaccine candidate. • The company...
Moderna's second quarter revenue of $145 million beats estimates amid a key pipeline setback.
Moderna reported second quarter 2026 revenue of $145 million, up from $142 million in the prior-year period, alongside a net loss per share of $1.97, an...
🟢 Moderna is trading 4.1% up today ahead of Q2 earnings and RSV vaccine traction
Moderna is trading 4.1% up at $60.27 as investors position ahead of its Q2 2026 earnings report on July 31 and monitor early traction for its RSV vaccine,...